stockrowSummit Therapeutics PLC
SMMT Healthcare Biotechnology
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.
- EPS
- +63.2%
- Free cash flow
- −112.8%
Quarter to June 2026, against a year earlier
Follow SMMT
Alert me
Summit Therapeutics PLC (SMMT) Price to free cash flow
Summit Therapeutics PLC has no meaningful price to free cash flow: its trailing twelve-month free cash flow is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 202× (December 2015) — the current reading is the lowest in ten years.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2017 | 2.0× | (57.98%) |
| FY2016 | 4.8× | — |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Dec 2022 | 0.0× | — |
| Sep 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| Mar 2022 | 0.0× | — |
| 23 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| KYMR Kymera Therapeutics, Inc. compare | n/m |
| SMMT Summit Therapeutics PLC | n/m |
| BBIO BridgeBio Pharma, Inc. compare | n/m |
| PCVX Vaxcyte, Inc. compare | n/m |
| HALO Halozyme Therapeutics, Inc. compare | 15.9× |
| BMRN BioMarin Pharmaceutical Inc. compare | 20.0× |
| JAZZ Jazz Pharmaceuticals PLC compare | 22.2× |
| ASND Ascendis Pharma A/S compare | 42.1× |
| TECH Bio-Techne Corp compare | 43.1× |
| Biotechnology industry median | 24.8× |
| Healthcare sector median | 21.1× |
| Market median | 14.1× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on SMMT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement